Reunion Neuroscience Inc. (TSE:REUN – Get Free Report)’s share price fell 2.7% during trading on Monday . The company traded as low as C$1.41 and last traded at C$1.42. 339 shares were traded during mid-day trading, a decline of 97% from the average session volume of 12,447 shares. The stock had previously closed at C$1.46.
Reunion Neuroscience Price Performance
The company’s 50-day moving average is C$1.43. The firm has a market cap of C$16.64 million, a price-to-earnings ratio of -0.43 and a beta of 4.20.
Reunion Neuroscience Company Profile
Reunion Neuroscience Inc, a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Further Reading
- Five stocks we like better than Reunion Neuroscience
- Airline Stocks – Top Airline Stocks to Buy Now
- The Charles Schwab Company Can Hit New Highs
- What is a Secondary Public Offering? What Investors Need to Know
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Business Services Stocks Investing
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
